STS Annual Meeting |  January 29-31, 2021


The STS Annual Meeting will take place virtually this year. The program will be available both in a live and on-demand format.  Be sure to stop by our virtual booth #104V or attend one of our industry symposiums.

Registration with STS is required to attend any of our industry symposiums.  Please see STS for further details,

New Frontiers in Treating Aortic Arch Disease*

Saturday, Jan 30th at 10:00 am – 11:00 am EST

Add event to calendar

Apple Google Office 365 Outlook Yahoo

This symposium will highlight two new therapies for treating aortic arch disease, the AMDS Hybrid Prosthesis for acute Type A dissections and the E-vita OPEN NEO total arch repair device. Faculty will discuss case presentations, highlight product design aspects, review clinical evidence to date on the therapies, and present their algorithm for treatment of these disease states. The symposium will conclude with a live Q&A session.


Prof. Jorg Kempfert

German Heart Center
Berlin, Germany

Dr. Michael Moon

Mazankowski Alberta Heart Institute
Edmonton, Canada

Prof. Tomas Holubec

University Hospital Frankfurt and Johann Wolfgang Goethe University Frankfurt  
Frankfurt, Germany

*This industry symposium will be held in conjunction with the STS Annual Meeting. It is not part of the official STS scientific program. Continuing Medical Education (CME) credit for this activity is not offered by STS.

SAVR: A Procedure Not a Product, Long-Term Data & New Horizons*

Sunday, Jan 31st at 1:30 pm – 2:30 pm EST

Add event to calendar

Apple Google Office 365 Outlook Yahoo

Long active lives come from thoughtful, informed decisions. Today, there are multiple options for aortic valve replacement. Which option is best for your patient? Join us for an engaging discussion on the advances in mechanical heart valves, the benefit of restored life expectancy with the Ross Procedure, and the possibility of a mechanical AVR without warfarin with a review of the PROACT Xa study design.


Dr. James Hermiller   

St. Vincent Heart Center
Indianapolis, IN

Dr. Ismail El-Hamamsy

Mount Sinai
New York, NY

Dr. Doug Johnston

Cleveland Clinic
Cleveland, OH

*This industry symposium will be held in conjunction with the STS Annual Meeting. It is not part of the official STS scientific program. Continuing Medical Education (CME) credit for this activity is not offered by STS.

Our Evolving Innovations


AMDS® Hybrid Prosthesis

The World’s First Aortic Arch Remodeling Device

Learn More

Prosthetic Heart Valves

The Only Aortic Mechanical Heart Valve FDA and CE Approved With Less Warfarin

Learn More

E-vita® OPEN NEO Hybrid Stent Graft

The Next Generation System For Aortic Arch &  Descending Aortic Repair With FET

Learn More

CryoValve®  SG Pulmonary Human Heart Valve

The First and Only Decellularized Pulmonary Human Heart Valve Cleared By The FDA

Learn More

NEXUSAortic Arch Stent Graft System by Endospan LTD

The First CE Approved Branched Device For Endovascular Repair Of The Aortic Arch

Learn More

PhotoFix® Decellularized Bovine Pericardium

No Aldehyde Chemistry Used In Any Part of The Process And Ready To Use

Learn More

BioGlue® Surgical Adhesive

The Only FDA Approved Product To Seal Anastomoses And To Reinforce And Adhere Tissues

Learn More

Chord-X® Mitral Chordal Replacement

Designed to Save Time, Allow Reproducible Results, & Simplify Procedures

Learn More

On-X Life Technologies, Inc., JOTEC GmbH, and Ascyrus Medical, GmbH are wholly owned subsidiaries of CryoLife, Inc. On-X Prosthetic Heart Valves are manufactured by On-X Life Technologies, Inc. The E-vita OPEN NEO is manufactured by JOTEC GmbH. NEXUS is manufactured by Endospan Ltd and distributed by JOTEC GmbH.  Products are not available in all Markets.

The snowflake design, CryoLife, Life Restoring Technologies, JOTEC, Ascyrus Medical, On-X, CryoValve, BioGlue, PhotoFix, and Chord-X are registered trademarks owned by CryoLife, Inc. or its subsidiaries. All other registered trademarks are owned by their respective owners.

© 2021 CryoLife, Inc. All rights reserved.  

Clinical Trials

As CryoLife continues to evolve as a company, clinical trials remain at the core of our business strategy.  Check out additional details on some of our ongoing clinical trials.